Christopher Sweeney

Christopher Sweeney

UNVERIFIED PROFILE

Are you Christopher Sweeney?   Register this Author

Register author
Christopher Sweeney

Christopher Sweeney

Publications by authors named "Christopher Sweeney"

Are you Christopher Sweeney?   Register this Author

100Publications

3074Reads

20Profile Views

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Prostate Cancer Prostatic Dis 2019 Sep 14;22(3):420-427. Epub 2019 Jan 14.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0121-2
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0121-2DOI Listing
September 2019

Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.

Eur Urol Oncol 2019 Sep 4;2(5):475-482. Epub 2018 Oct 4.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.09.003DOI Listing
September 2019

Informing efficient pilot development of animal trauma models through quality improvement strategies.

Lab Anim 2019 Aug 9;53(4):394-404. Epub 2018 Oct 9.

3 Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0023677218802999DOI Listing
August 2019

AYA testis cancer: The unmet challenge.

Pediatr Blood Cancer 2019 Aug 7;66(8):e27796. Epub 2019 May 7.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27796DOI Listing
August 2019

DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues .

Radiat Res 2019 Aug 16;192(2):231-239. Epub 2019 May 16.

a Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1667/RR15404.1DOI Listing
August 2019

Body Mass Index and Outcomes in Germ-Cell Tumors.

Clin Genitourin Cancer 2019 Aug 25;17(4):283-290. Epub 2019 Apr 25.

Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.04.012DOI Listing
August 2019

What Does Metastasis-Free Survival Actually Mean?

J Clin Oncol 2019 Jul 3;37(19):1679-1680. Epub 2019 May 3.

Christopher J. Sweeney, MBBS, Dana-Farber Cancer Institute, Boston, MA; Richard De Abreu Lourenco, PhD, University of Technology Sydney, Sydney, NSW, Australia; Anis A. Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA; and Marc Buyse, ScD, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.02372DOI Listing
July 2019

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

N Engl J Med 2019 07 2;381(2):121-131. Epub 2019 Jun 2.

From Monash University (I.D.D., M.F., D.W.P.), Eastern Health (I.D.D.), Australian Urology Associates (M.F.), Monash Health (D.W.P.), and the Peter MacCallum Cancer Centre and the University of Melbourne (S.K.S., S.G.W.), Melbourne, VIC, the National Health and Medical Research Council Clinical Trials Centre, University of Sydney (A.J.M., M.R.S., X.C., W.E.H., E.T., S.Y., A.Y.Z.), the Chris O'Brien Lifehouse (M.R.S., L.G.H., A.Y.Z.), the University of Sydney (L.G.H., G.M.), Royal Prince Alfred Hospital (L.G.H.), Kinghorn Cancer Centre, St. Vincent's Hospital, and Garvan Institute of Medical Research (A.M.J.), Macquarie University (A.Y.Z.), and Western Sydney University (R.R.Z.), Sydney, Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW (M.R.S.), Port Macquarie Base Hospital and Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, NSW (S.B.), Sydney Adventist Hospital, Wahroonga, NSW (G.M.), the ANZUP Cancer Trials Group, Camperdown, NSW (M.M.), the Adelaide Cancer Centre and the University of Adelaide (F.P.) and the Royal Adelaide Hospital (T.H.T.), Adelaide, SA, and Orange Health Service, Central West Cancer Care Centre, Orange, NSW (R.R.Z.) - all in Australia; BC Cancer and the University of British Columbia, Vancouver (K.N.C.), the Cross Cancer Institute and the University of Alberta, Edmonton (S.A.N.), Canadian Cancer Trials Group, Queen's University (W.P., F.V.-B.), and the Kingston Health Sciences Center (F.V.-B.), Kingston, ON, and the University of Ottawa and the Ottawa Hospital Research Institute, Ottawa (M.N.R.) - all in Canada; Guy's and St. Thomas' NHS Foundation Trust Biomedical Research Centre, Cancer Research UK and King's College London, and Sarah Cannon Research UK, London (S.C.), and the Royal Cornwall Hospital, Truro (A. Thomson) - all in the United Kingdom; Auckland City Hospital, Auckland (N.J.L.), and the Waikato District Health Board, Hamilton (A. Tan) - both in New Zealand; Cancer Trials Ireland (J.M., R.M.), Mater Misericordiae University Hospital (J.M.), and St. Vincent's University Hospital and University College Dublin (R.M.D.) - all in Dublin; and Dana-Farber Cancer Institute and Harvard Medical School (C.J.S.) - both in Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1903835DOI Listing
July 2019

Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic mice.

Drug Dev Res 2019 Jul 13. Epub 2019 Jul 13.

Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ddr.21565DOI Listing
July 2019

Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart.

J Clin Oncol 2019 Apr 22;37(10):765-769. Epub 2019 Feb 22.

4 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01927DOI Listing
April 2019

Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany.

BJU Int 2019 Mar 9;123(3):385-387. Epub 2018 Dec 9.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14616DOI Listing
March 2019

Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer.

Eur Urol Focus 2019 03 18;5(2):111-113. Epub 2019 Mar 18.

Dana Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.03.008DOI Listing
March 2019

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Eur Urol 2019 02 14;75(2):285-293. Epub 2018 Aug 14.

The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.07.035DOI Listing
February 2019

Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era.

Clin Genitourin Cancer 2019 Feb 19;17(1):58-64.e1. Epub 2018 Sep 19.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.09.009DOI Listing
February 2019

Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide.

Clin Exp Metastasis 2018 10 23;35(7):649-661. Epub 2018 Jun 23.

Molecular Medicine and Pathology, Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-018-9915-9DOI Listing
October 2018

Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?

Eur Urol 2018 10 12;74(4):420-421. Epub 2018 Jul 12.

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.06.036DOI Listing
October 2018

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

Prostate Cancer Prostatic Dis 2018 09 20;21(3):306-318. Epub 2017 Dec 20.

Duke University Medical Center and Cancer Institute, Duke Prostate and Urologic Cancer Center, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-017-0014-9DOI Listing
September 2018

Reply to J.J. Tao et al.

J Clin Oncol 2018 08 1;36(23):2451. Epub 2018 Jun 1.

John D. Hainsworth, Sarah Cannon Research Institute; Tennessee Oncology, PLLC, Nashville, TN; Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Genentech, South San Francisco, CA; David R. Spigel, Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Christopher Sweeney, Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, PLLC, Nashville, TN; Ron Bose, Washington University School of Medicine, St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San Francisco, CA; and Razelle Kurzrock, Moores Cancer Center, University of California, San Diego, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6392DOI Listing
August 2018

Interventional vitamin C: A strategy for attenuation of coagulopathy and inflammation in a swine multiple injuries model.

J Trauma Acute Care Surg 2018 07;85(1S Suppl 2):S57-S67

From the Department of Anesthesiology (P.S.R., B.D.S.), Department of Internal Medicine (B.J.F., J.M., C.S., P.M., M.E., E.F., A.A.F., R.N.), Department of Pharmacotherapy and Outcomes Science (E.J.M., D.F.B.), Virginia Commonwealth University, Richmond, Virginia; Department of Anesthesiology (P.S.R., B.D.S.), University of Florida, Gainesville, Florida; and Naval Medical Center Portsmouth (R.N.), Portsmouth, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TA.0000000000001844DOI Listing
July 2018

Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce.

Am J Med 2018 05 16;131(5):517-523. Epub 2018 Mar 16.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2017.11.039DOI Listing
May 2018

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

J Clin Oncol 2018 04 31;36(11):1080-1087. Epub 2018 Jan 31.

Christos E. Kyriakopoulos, Glenn Liu, and David F. Jarrard, University of Wisconsin (UW) School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI; Yu-Hui Chen and Christopher J. Sweeney, Dana-Farber Cancer Institute; Yu-Hui Chen, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group; Christopher J. Sweeney, Harvard Medical School, Boston, MA; Michael A. Carducci, Noah M. Hahn, and Mario Eisenberger, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Daniel H. Shevrin, NorthShore University HealthSystem, Evanston; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Matthew M. Cooney, Seidman Cancer Center, University Hospitals Cleveland Medical Center; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129PMC
April 2018

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

J Clin Oncol 2018 04 9;36(11):1088-1095. Epub 2018 Mar 9.

Alicia K. Morgans, Maha Hussain, and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Yu-Hui Chen and Christopher J. Sweeney, Dana Farber Cancer Institute, Boston, MA; David F. Jarrard, University of Wisconsin Hospital and Clinics, Madison, WI; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Elizabeth R. Plimack and Benjamin A. Gartrell, Montefiore Medical Center, Bronx, NY; Michael A. Carducci, Johns Hopkins University, Baltimore, MD; Jorge A. Garcia, Cleveland Clinic, Cleveland, OH; Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY; and Linda J. Patrick-Miller, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891128PMC
April 2018

Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.

Cancer 2018 03 19;124(5):925-933. Epub 2017 Dec 19.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31154DOI Listing
March 2018

Current treatment strategies for advanced prostate cancer.

Int J Urol 2018 03 20;25(3):220-231. Epub 2017 Dec 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053280PMC
March 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.3921
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.3921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805480PMC
February 2018

Reply to Y. Zhu et al.

J Clin Oncol 2018 02 21;36(5):515-516. Epub 2017 Dec 21.

Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.2872
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.2872DOI Listing
February 2018

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

J Clin Oncol 2018 02 10;36(6):536-542. Epub 2018 Jan 10.

John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Ron Bose, Washington University School of Medicine, St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California San Diego, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3780DOI Listing
February 2018

Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy.

Eur Urol Focus 2017 12 26;3(6):621-628. Epub 2016 Oct 26.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.10.005DOI Listing
December 2017

Chemotherapy for oligometastatic prostate cancer.

Curr Opin Urol 2017 Nov;27(6):553-558

aDivision of Medical Oncology, USC Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, California bDana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000446DOI Listing
November 2017

A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.

JCO Clin Cancer Inform 2017 11;1:1-15

Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00018DOI Listing
November 2017

Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer.

Clin Genitourin Cancer 2017 10 28;15(5):563-569.e3. Epub 2016 Oct 28.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.10.011DOI Listing
October 2017

Prostate cancer: A new standard-of-care for advanced-stage disease.

Nat Rev Clin Oncol 2017 10 8;14(10):592-593. Epub 2017 Aug 8.

Department of Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.120DOI Listing
October 2017

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

J Clin Oncol 2017 09 10;35(27):3097-3104. Epub 2017 Aug 10.

Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer Institute, Boston, MA; Marc Buyse, International Drug Development Institute; Bertrand Tombal, Université Catholique de Louvain, Louvain-la-Neuve; Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor, Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation, Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA; Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, University College London, London, United Kingdom; James J. Dignam, University of Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France; Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652387PMC
September 2017

Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies.

Clin Genitourin Cancer 2017 Sep 8. Epub 2017 Sep 8.

Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673173027
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2017.08.019DOI Listing
September 2017

Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors.

Clin Genitourin Cancer 2017 Aug 3. Epub 2017 Aug 3.

Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.024DOI Listing
August 2017

Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.

Brachytherapy 2016 Nov - Dec;15(6):695-700. Epub 2016 Aug 12.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2016.07.001DOI Listing
July 2017

"Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer.

Eur Urol 2017 07 7;72(1):1-3. Epub 2017 Mar 7.

Institut de Recherche Clinique, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.02.036DOI Listing
July 2017

Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo.

Radiat Res 2017 05 3;187(5):501-512. Epub 2017 Mar 3.

a   Molecular Medicine and Pathology, Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1667/RR14710.1DOI Listing
May 2017

Approach to Oligometastatic Prostate Cancer.

Am Soc Clin Oncol Educ Book 2016 ;35:119-29

From the Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Mayo Clinic, Rochester, MN; University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159241DOI Listing
January 2017

Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.

J Oncol Pract 2017 01 3;13(1):9-18. Epub 2017 Jan 3.

UConn Health, Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.018523DOI Listing
January 2017

Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists.

Eur Urol Focus 2016 Dec 13;2(5):463-464. Epub 2016 Dec 13.

Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.11.017DOI Listing
December 2016

Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer.

Eur Urol Focus 2016 Dec 23;2(5):488-498. Epub 2016 Nov 23.

Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.10.008DOI Listing
December 2016

Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors.

Cancer 2016 Oct 8;122(20):3127-3135. Epub 2016 Aug 8.

Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048492PMC
http://dx.doi.org/10.1002/cncr.30159DOI Listing
October 2016

Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.

Eur Urol 2016 09 13;70(3):410-2. Epub 2016 May 13.

Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838163015
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2016.05.002DOI Listing
September 2016

It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer.

Eur Urol 2016 08 9;70(2):263-4. Epub 2015 Dec 9.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.11.025DOI Listing
August 2016

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Clin Genitourin Cancer 2016 08 17;14(4):e299-305. Epub 2015 Dec 17.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.12.008DOI Listing
August 2016

CT restaging of testicular germ cell tumors: The incidence of isolated pelvic metastases.

Eur J Radiol 2016 Aug 4;85(8):1439-44. Epub 2016 Jun 4.

Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2016.06.002DOI Listing
August 2016

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

J Clin Oncol 2016 06 4;34(16):1913-20. Epub 2016 Apr 4.

Rana R. McKay, Lillian Werner, Christopher J. Sweeney, Philip W. Kantoff, and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston; Robert W. Ross, Bluebird Bio, Cambridge, MA; Amado J. Zurita and Hai T. Tran, MD Anderson Cancer Center, Houston, TX; Justine Y. Bruce, University of Wisconsin Carbone Cancer Center, Madison, WI; Michael A. Carducci, Johns Hopkins University; Arif Hussain, Greenebaum Cancer Center, Baltimore, MD; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Elisabeth I. Heath, Karmanos Cancer Institute, Detroit, MI; and Philip W. Kantoff and Susan F. Slovin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321094PMC
June 2016

Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer.

J Clin Oncol 2016 06 11;34(16):1905-12. Epub 2016 Apr 11.

Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.1969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966343PMC
June 2016

Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors.

Clin Cancer Res 2016 05 2;22(9):2183-9. Epub 2015 Dec 2.

Broad Institute of MIT and Harvard, Cambridge, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854770PMC
May 2016

Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.

Proc Natl Acad Sci U S A 2016 May 16;113(22):6259-64. Epub 2016 May 16.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; Harvard Medical School, Boston, MA 02215

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1600420113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896695PMC
May 2016

Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.

J Natl Compr Canc Netw 2016 04;14(4):421-8

Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

View Article

Download full-text PDF

Source
April 2016

Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer.

PLoS Comput Biol 2016 Apr 14;12(4):e1004820. Epub 2016 Apr 14.

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pcbi.1004820DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831844PMC
April 2016

Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.

J Clin Oncol 2016 Mar 19;34(7):714-20. Epub 2016 Jan 19.

Jenny J. Ko, Abbotsford Cancer Agency, Abbotsford, British Columbia; Haocheng Li, University of Calgary; Igor Stukalin, Nimira Alimohamed, and Daniel Y.C. Heng, Tom Baker Cancer Center, Calgary, Alberta; Tehmina Asif, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan; Daphne Day and Philippe L. Bedard, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Brandon Bernard and Christopher J. Sweeney, Dana Farber Cancer Institute, Boston, MA; and Ben Tran and Margaret Lee, Royal Melbourne Hospital, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.7909DOI Listing
March 2016

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

J Clin Oncol 2016 Feb 12;34(4):345-51. Epub 2015 Oct 12.

Darren R. Feldman, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY; Anja Lorch, University Hospital Düsseldorf, Düsseldorf; Carsten Bokemeyer, University Hospital Eppendorf, Hamburg, Germany; Andrew Kramar, Centre Oscar Lambret, Lille; Aude Flechon and Helen Boyle, Centre Léon Bérard, Lyon, France; Costantine Albany and Lawrence H. Einhorn, Indiana University, Bloomington, IN; Patrizia Giannatempo and Andrea Necchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milano; Teodoro Sava, Azienda Ospedaliera Universitaria Integrata di Verona, Verona; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Meldola, Italy; Peter Chung, Princess Margaret Cancer Centre, University of Toronto, Toronto; Eric William Winquist, London Health Sciences Center, London, Ontario, Canada; Robert A. Huddart, Royal Marsden Hospital; Thomas Powles, St Bartholomew's Hospital, London, United Kingdom; Alexey Tryakin, Blokhin's Russian Cancer Research Center, Moscow, Russia; Jorge Aparicio, University Hospital Le Fe, Valencia, Spain; Christopher J. Sweeney, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gabriella Cohn Cedermark, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; and Jörg Beyer, UniversitätsSpital Zürich, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.7000
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.7000DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070579PMC
February 2016

Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012.

Urol Oncol 2016 Feb 23;34(2):57.e15-22. Epub 2015 Oct 23.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women׳s Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.09.002DOI Listing
February 2016

Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer.

N Engl J Med 2016 01;374(3):287

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1511800DOI Listing
January 2016

The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy.

JAMA Oncol 2015 Dec;1(9):1270-1

Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.3005DOI Listing
December 2015

Diagnosis and Treatment of Testicular Cancer: A Clinician's Perspective.

Surg Pathol Clin 2015 Dec;8(4):717-23

Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, 450 Brookline Avenue, D1230, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.path.2015.07.006DOI Listing
December 2015

Relationship Between the Pathologic Subtype/Initial Stage and Microliths in Testicular Germ Cell Tumors.

J Ultrasound Med 2015 Nov 22;34(11):1977-82. Epub 2015 Sep 22.

Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts USA (F.S., M.H.R., S.H.T., S.A.H.); Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts USA (F.S., M.H.R., S.H.T., S.A.H.); Harvard Medical School, Boston, Massachusetts USA (M.J.W.); and Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts USA (C.S.).

View Article

Download full-text PDF

Source
http://www.jultrasoundmed.org/content/34/11/1977.full.pdf
Web Search
http://www.jultrasoundmed.org//cgi/doi/10.7863/ultra.14.0903
Publisher Site
http://dx.doi.org/10.7863/ultra.14.09031DOI Listing
November 2015

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.

Int J Radiat Oncol Biol Phys 2015 Nov 29;93(4):828-35. Epub 2015 Jul 29.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.07.2281DOI Listing
November 2015